TITLE

Rules that extend drug patents face challenge

AUTHOR(S)
Sibbald, Barbara
PUB. DATE
October 2003
SOURCE
CMAJ: Canadian Medical Association Journal;10/28/2003, Vol. 169 Issue 9, p950
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on an investigation being conducted by the Competition Bureau of Canada into whether a method of prolonging drug patents contravenes Canadian law, as of October 2003. Factor which led to the review; Threat posed by the runaway cost of drugs to public medical care, according to Mike Luff, spokesperson for the National Union of Public and General Employees; Allegations of the coalition against companies that underwrites the development of new drugs.
ACCESSION #
11106028

 

Related Articles

  • Savings for drugs coming off patent could be huge.  // Employee Benefit News Canada in Brief;12/2/2008, p5 

    The article reports on the study from the Canada Competition Bureau which found that plan sponsors and plan members could save hundreds of millions of dollars in the coming years as more major drugs lose patent protection. The study further reveals that drugs scheduled to come off patent over...

  • A return to patent good sense.  // Nature Reviews Drug Discovery;Jul2002, Vol. 1 Issue 7, p483 

    Editorial. Reports on the status of patent protection in relation to drug development in the U.S. Doctrine of equivalents; Prosecution history estoppel.

  • Could Canada's compulsory Rx licensing work in U.S.? Conlan, Michael F. // Drug Topics;8/16/93, Vol. 137 Issue 16, p56 

    Discusses the effects of changes in Canada's patent laws on its prescription drug prices. Introduction of legislation in Congress to create a United States version of Canada's Patented Medicines Price Review Board (PMPRB); Canada as having highest new drug prices; Compulsory licensing; Length...

  • Rulings may clear pathway for generic Neurontin, Paxil. Liebman, Milton // Medical Marketing & Media;Feb2003, Vol. 38 Issue 2, p18 

    Reports on the court ruling on the pending applications for a generic form of Neurontin in the U.S. Background of the case; Actions taken by the Food and Drug Administration; Importance of the federal court's patent decision.

  • Canadian agency ends probe of theater circuits.  // Hollywood Reporter -- International Edition;12/17/2002, Vol. 376 Issue 28, p67 

    Reports that the Canadian federal Competition Bureau has abandoned a two-year old investigation into allegations that the country's two largest theater chains have denied first-run Hollywood movies to rival circuits. Complaint rejected by the agency; Economic analysis commissioned by the...

  • Closing the FDA's Orange Book. Hollis, Aidan // Regulation;Winter2001, Vol. 24 Issue 4, p14 

    Examines the monopoly impact of the process of listing drug patents by pharmaceutical companies under the Drug Price Competition and Patent Term Restoration Act. Impact of the Act on the price competition in the drug market; How other patents work; Cost of the delay of the entry of generic...

  • The protection of a product obtained by a patented process under German law. Bühling, Jochen // Journal of Intellectual Property Law & Practice;Aug2013, Vol. 8 Issue 8, p651 

    The article presents information on the protection of a product gained by a patented process under German law. Section 9 of the German Patent Act mandates the protection of product patents and process patents. While product claims protect a particular product, for example, a device, a chemical...

  • Drug firms demand change on Patent Bill.  // Chemical Business;Dec98, Vol. 12 Issue 12, p98 

    Reports that drug manufacturers in India have demanded product patent rights instead of exclusive marketing rights sought for potential patent applicants. Differences in approval time between product patents and exclusive marketing rights; How marketing rights could provide entry for foreign...

  • Patent expirations spell big changes for generic industry. Cassell, Dana K. // Drug Topics;8/6/2001 Supplement, Vol. 145 Issue 15, p9 

    Focuses on the increase of patent expirations among pharmaceutical industries in the United States. List of top eight drugs going off patent before December 2005; Delay of patent expiration due to court trials; Plan of an educational campaign on safety and efficacy of generic drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics